Pall Corp. has agreed to acquire ForteBio, Inc., a provider of advanced analytical systems. The transaction is expected to close by February of 2012. Upon closing, ForteBio will become a wholly-owned subsidiary of Pall Corp. Terms of the deal were not disclosed. ForteBio has a portfolio of innovative, label-free protein analysis instruments that will extend Pall’s capabilities in the $1 billion-plus biopharma process monitoring market and in the protein research market. The analytical systems,...